Welcome to our dedicated page for Koru Med Sys news (Ticker: KRMD), a resource for investors and traders seeking the latest updates and insights on Koru Med Sys stock.
KORU Medical Systems Inc (KRMD) specializes in innovative subcutaneous infusion systems for critical therapies. This hub provides authorized updates about the company's medical device developments, regulatory milestones, and strategic initiatives.
Investors and healthcare professionals will find timely announcements including product launch details, financial disclosures, and manufacturing updates. Our curated collection ensures access to verified information about FREEDOM infusion systems and related technologies.
Key updates cover FDA clearances, partnership announcements, clinical application insights, and operational developments. All content maintains strict compliance with financial disclosure regulations and medical device reporting standards.
Bookmark this page for streamlined access to KRMD's latest advancements in immunoglobulin therapy delivery systems. Check regularly for official updates directly impacting the medical device sector and chronic care treatment landscapes.
KORU Medical Systems (NASDAQ: KRMD) has announced that it will report its first quarter 2023 financial results on May 4, 2023. The management will host a conference call at 4:30 p.m. ET to discuss these results and provide updates on corporate developments. The call can be accessed by dialing (800)-734-8507 for U.S. participants, or (212)-231-2925 for international calls, using conference ID: 22026692. A live and archived webcast will also be available on the company’s website. KORU Medical focuses on innovative subcutaneous drug delivery systems designed to enhance patient quality of life, with products like the FREEDOM Syringe Infusion System.
KORU Medical Systems, Inc. (NASDAQ: KRMD) reported strong financial results for Q4 and the full year 2022, achieving a 13% increase in net revenue for Q4 to $7.3 million and 19% growth for the year, totaling $27.9 million. The company saw significant growth in its Novel Therapies business, with revenues skyrocketing 259.9% in Q4, thanks to new collaborations. Although the gross profit increased by 6.4%, it dropped as a percentage of revenue to 55.5% due to rising manufacturing costs. The company anticipates 2023 revenue between $32.5 million and $33.5 million, representing a 17-20% growth.
FAQ
What is the current stock price of Koru Med Sys (KRMD)?
What is the market cap of Koru Med Sys (KRMD)?
